Abemaciclib has a lesser impact on neutrophils maturation in vitro than other CDK4 & 6, which is consistent with lower incidences of neutropenia observed in clinical settings and may allow for a prolonged treatment. This evidence concerns the gene CDK4 and Decreased total neutrophil count.